RAD Achieves Partial Response in Phase 1 Trial of RAD204

• First RECIST-confirmed durable Partial Response at highest dose level
• Second patient shows early tumor shrinkage and remains progression-free
• RAD204 well-tolerated with no dose-limiting toxicities observed
• Positive initial data supports the therapeutic potential of RAD204

Radiopharm Theranostics announced updated results from the ongoing Phase 1 trial of RAD204, its PD-L1-targeted lutetium-177 nanobody radiotherapeutic, in patients with advanced solid tumors post-immunotherapy. The trial's third cohort, at the highest dose level of 90 mCi, achieved a confirmed durable partial response in the first patient, with a 43% reduction in target lesions. The patient remains progression-free beyond seven months. The second patient showed early tumor shrinkage and is also progression-free. RAD204 has demonstrated a favorable safety profile with no dose-limiting toxicities observed. These results support the therapeutic potential of RAD204 in PD-L1-associated malignancies.